Lung Cancer Clinical Trial

Prospective Clinicogenomic Program

Summary

The main purpose of this study is to evaluate the feasibility of a scalable, prospective research program for participants with metastatic non-small cell lung cancer (mNSCLC) or extensive-stage small-cell lung cancer (ES-SCLC) planning to start standard-of-care (SOC) systemic anti-cancer treatment. The study will also examine ctDNA status over the course of treatment as a predictor of response to therapy.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Documented diagnosis of mNSCLC or ES-SCLC
Planned initiation of SOC systemic anti-cancer treatment
Front-Line Immunotherapy Cohort: Received front-line treatment of an immune blockade therapy including anti-CTLA-4, anti-PD-1, or anti-PD-L1 therapeutic antibody on Protocol GX41563

Exclusion Criteria:

- Participant actively receiving investigational medicinal product(s) as part of an interventional trial at the time of signing informed consent

Study is for people with:

Lung Cancer

Phase:

Phase 4

Estimated Enrollment:

1000

Study ID:

NCT04180176

Recruitment Status:

Active, not recruiting

Sponsor:

Genentech, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 23 Locations for this study

See Locations Near You

Alabama Oncology
Birmingham Alabama, 35205, United States
Clearview Cancer Institute
Huntsville Alabama, 35805, United States
Ironwood Cancer & Research Centers
Chandler Arizona, 85224, United States
Yale University
New Haven Connecticut, 06510, United States
Florida Cancer Specialists; Department of Oncology
Fort Myers Florida, 33901, United States
Florida Cancer Specialist, North Region
Saint Petersburg Florida, 33705, United States
SCRI Florida Cancer Specialists PAN
Tallahassee Florida, 32308, United States
Florida Cancer Specialists
West Palm Beach Florida, 33401, United States
University Cancer & Blood Center, LLC; Research
Athens Georgia, 30607, United States
Piedmont Cancer Institute, PC
Atlanta Georgia, 30318, United States
Fort Wayne Med Oncology & Hematology Inc
Fort Wayne Indiana, 46845, United States
Cancer & Hematology Centers of Western Michigan
Grand Rapids Michigan, 49503, United States
Jackson Oncology Associates, PLLC
Jackson Mississippi, 39202, United States
Southeast Nebraska Cancer Ctr
Lincoln Nebraska, 68510, United States
Regional Cancer Care Associates LLC, Central Jersey Division
East Brunswick New Jersey, 08816, United States
Hematology Oncology Associates of Central New York
East Syracuse New York, 13057, United States
West Clinic
New York New York, 10055, United States
National Translational Research Group
Port Jefferson Station New York, 11776, United States
Oklahoma Cancer Specialists and Research Institute
Tulsa Oklahoma, 74146, United States
SCRI Tennessee Oncology Chattanooga
Chattanooga Tennessee, 37404, United States
Tennessee Oncology
Nashville Tennessee, 37203, United States
Hematology Oncology Associates of Fredericksburg, Inc.
Fredericksburg Virginia, 22408, United States
Virginia Cancer Institute - Richmond
Richmond Virginia, 23236, United States

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 4

Estimated Enrollment:

1000

Study ID:

NCT04180176

Recruitment Status:

Active, not recruiting

Sponsor:


Genentech, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.